BSE filing, NSE: VENUSREM. Summary written from the filing by ALFA Finder's alert engine.
Venus Remedies Ltd: key numbers
- Share price
- ₹1,303.60
- Market cap
- ₹1,743 Cr
- Revenue (annual)
- ₹769.6 Cr
- Net profit (annual)
- ₹102.8 Cr
- P/E (TTM)
- 14.3×Sector 46.1×
- Promoter holding
- 41.76%+0.00% QoQ
- FII holding
- 3.14%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Venus Remedies Ltd
All →Venus Remedies Q2 FY27 Results: Net Profit ₹25.6 Cr, Up 27.4% YoY
Venus Remedies Ltd reported revenue from operations of ₹218.8 Cr (+13.5% YoY) and net profit of ₹25.6 Cr (+27.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹25.6 Cr · +27.4% YoY
Venus Remedies Regulatory Approval
Venus Remedies Limited secured five marketing authorizations for drugs including Vancomycin and Meropenem across Kazakhstan, Peru, Kuwait, and Argentina. These regulatory approvals expand its global pharmaceutical portfolio.
Venus Remedies Board Meeting Date
Venus Remedies will hold a board meeting on 26th October 2026 to consider and approve its unaudited standalone and consolidated financial results for the September quarter.
Venus Remedies Other Announcement
Venus Remedies Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026, as required by SEBI regulations.
Venus Remedies Other Announcement
Venus Remedies Limited has announced a change in its Corporate Identification Number (CIN) following the alteration of its Memorandum of Association.
Venus Remedies Other Announcement
Venus Remedies Limited has informed the exchanges about its social media posts regarding a special window for the re-lodgement of physical share transfer requests.
Other management change announcements
All →Travel Food Services Management Change
Travel Food Services appointed Avinash Yogeshwar as Senior Managerial Personnel, effective 29 October 2026. It is a senior leadership change with no financial impact.
Swan Defence and Heavy Industries Management Change
Swan Defence designated three existing employees as Senior Management Personnel effective 29 October 2026, following organisational restructuring. The move reflects leadership reorganisation, not new capital or contracts.
Prima Innovation Management Change
Prima Innovation Limited reported the resignation of Non-Executive Director Dilip M. Parekh, effective 29-10-2026, citing personal reasons. The exit is a board-level change investors should note.
Strides Pharma Science Management Change
Strides Pharma's board appointed Biren Gabhawala as Non-Executive Independent Director effective November 1, 2026, for five years. He is a Chartered Accountant with extensive audit and listed-company board experience.
- Execution
- Five-year term effective November 1, 2026
Srivasavi Adhesive Tapes Management Change
Srivasavi Adhesive Tapes appointed Ms. Venugopal as Chief Financial Officer effective 29 October 2026. She holds an MBA in Finance with seven years of finance experience.
Restaurant Brands Asia Management Change
Restaurant Brands Asia appointed nine persons on October 29, 2026, including two directors, a CEO and senior management heads. Shivkumar Dega joins as a non-executive independent director.